Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04311502
Other study ID # ACTG A5362
Secondary ID 30148
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 16, 2021
Est. completion date June 23, 2024

Study information

Verified date July 2023
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with CFZ loading dose versus 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB).


Description:

This study will compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with CFZ loading dose versus 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB). Randomization will be stratified based on HIV status and the presence of advanced disease as determined by chest X-ray. Participants will be randomized to one of three arms: - Arm 1 (Experimental): rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + CFZ 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks - Arm 2 (SOC): rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks - Arm C (Pharmacokinetic [PK]-only subgroup): PHZE + CFZ 100 mg once daily for 4 weeks; then remain on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks) All participants must receive pyridoxine (vitamin B6) with each dose of isoniazid (INH) based on current local, national or international dosing guidelines. Arm 1 participants will be treated for 13 weeks (including a 2-week CFZ loading dose of 300 mg daily). Arm 2 participants will be treated for 26 weeks, and Arm C participants will be treated for 4 weeks. All participants in Arms 1, 2, and C will be followed from randomization to Week 65. Study visits may include physical examinations; blood, urine, and/or sputum collection; chest X-rays; and electrocardiograms (ECG).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 104
Est. completion date June 23, 2024
Est. primary completion date June 23, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by: - At least one sputum specimen positive for M. tuberculosis by molecular TB assay (Xpert) or line probe assay [LPA]) OR - At least one sputum specimen positive (1+ or greater) for acid-fast bacilli (AFB) on smear microscopy - Note: TB diagnosis for purposes of meeting inclusion criterion can be from a study testing laboratory or from an outside laboratory, as long as it is from a sputum sample collected within 5 days prior to entry. - Pulmonary TB diagnosed without known INH resistance (e.g., by LPA) and without known RIF resistance (e.g., by either LPA or Xpert). - Aged =18 years. - Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to entry OR - HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection. - For participants living with HIV, CD4+ cell count =100 cells/mm^3, obtained within 30 days prior to study entry at any network-approved non-US laboratory that is Immunology Quality Assessment (IQA) certified. - For participants living with HIV must be currently receiving or planning to initiate antiretroviral therapy (ART) at or before study week 8. - A verifiable address or residence readily accessible to facilitate directly observed therapy, and willingness to inform the study team of any change of address during the treatment and follow-up period. - The following laboratory values obtained at or within 5 days prior to entry by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs. - Serum or plasma alanine aminotransferase (ALT) =3 times the upper limit of normal (ULN) - Serum or plasma total bilirubin =2.5 times ULN - Serum or plasma creatinine =2 times ULN - Serum or plasma potassium =3.5 mEq/L and =5.5 mEq/L - Absolute neutrophil count (ANC) =650/mm^3 - Hemoglobin =7.0 g/dL - Platelet count =50,000/mm^3 - For females of reproductive potential, negative serum or urine pregnancy test within 5 days prior to entry by any US clinic or laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or is using a point of care (POC)/CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs. - Female participants of reproductive potential must agree not to participate in the conception process (i.e., active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable nonhormonal method of contraception, as listed below, while on study treatment and for 30 days after stopping study medications. - Acceptable forms of contraception include: - Condoms - Intrauterine device or intrauterine system - Cervical cap with spermicide - Diaphragm with spermicide - Note: Hormonal birth control alone is not acceptable, as it may not be sufficiently reliable in combination with RPT or RIF. - Female participants who are not of reproductive potential must have documentation of menopause (i.e., at least 1 year amenorrheic), hysterectomy, or bilateral oophorectomy or bilateral tubal ligation. - Documentation of Karnofsky performance score =50 within 30 days prior to entry. - Documentation of either the presence or absence of advanced disease as determined by chest X-ray within 5 days prior to entry. - Ability and willingness of participant to provide informed consent. Exclusion Criteria: - More than 5 days of treatment directed against active TB for the current TB episode preceding study entry. - Pregnant or breast-feeding. - Unable to take oral medications. - Current receipt of clofazimine or bedaquiline or known receipt of clofazamine or bedaquiline at any time in the past. - QTcF interval >450 ms for men or >470 ms for women within 30 days prior to entry. - Weight <30 kg. - Current or planned use within 6 months following enrollment of one or more of the following medications: HIV protease inhibitors, HIV entry and fusion inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (other than EFV), elvitegravir/cobicistat, bictegravir, quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine. - Current extrapulmonary TB, in the opinion of the site investigator. - Current or history of known personal or family long QT syndrome. - Known allergy/sensitivity or any hypersensitivity to components of study TB drugs or their formulation. - Active drug, alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Known history of acute intermittent porphyria. - Other medical conditions (e.g., severe uncontrolled diabetes, liver or kidney disease, blood disorders, peripheral neuritis, chronic diarrhea) in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clofazimine (CFZ)
Administered orally once daily
Rifapentine (RPT)
Administered orally once daily
Isoniazid (INH)
Administered orally once daily
Pyrazinamide (PZA)
Administered based on weight orally once daily
Ethambutol (EMB)
Administered based on weight orally once daily
Rifampicin (RIF)
Administered orally once daily
Dietary Supplement:
Pyridoxine (vitamin B6)
All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.

Locations

Country Name City State
Haiti Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS Port-au-Prince
India Byramjee Jeejeebhoy Medical College (BJMC) CRS Pune
Malawi Blantyre CRS Blantyre
Malawi Malawi CRS Lilongwe Central
South Africa CAPRISA eThekwini CRS Durban Kwa Zulu Natal
Zimbabwe Milton Park CRS Harare

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

Haiti,  India,  Malawi,  South Africa,  Zimbabwe, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to stable culture conversion in liquid media Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB Measured through Week 12
Primary Proportion of participants across study arms experiencing any Grade 3 or higher adverse event (AE) that is at least a one grade increase from baseline Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, July 2017 Measured through Week 65
Secondary Proportion of participants with favorable clinical/bacteriologic outcome Measured at Week 65
Secondary Proportion of participants with favorable composite outcome including treatment completion Measured at Week 65
Secondary Proportion of participants across study arms who prematurely discontinue their treatment regimen Defined as discontinuation other than due to violent death, natural disaster, or administrative censoring Measured through Week 65
Secondary Mean QTcF change from baseline Measured at Weeks 2, 8, and 13 (end of investigational treatment)
Secondary Occurrence of absolute QTcF =480 ms and =500 ms, and =500 ms at any time during study treatment Measured through Week 65
Secondary Occurrence of QTcF change from baseline of =30 ms and =60 ms, and =60 ms at any time during study treatment Measured through Week 65
Secondary Time to stable culture conversion in solid media Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB Measured through Week 65
Secondary Proportion of participants with culture conversion across all study arms Measured at Weeks 8 and 12
Secondary Proportion of participants with one or more serious adverse events (SAEs) Measured through Week 65
Secondary Time (days) to positivity in liquid culture (MGIT) after start of treatment across study arms Measured through Week 65
Secondary Change in chest X-ray score from baseline to end of treatment in each Arm (week 13 in Arm 1, week 26 in Arm 2) The chest X-ray will be posterior-anterior. Extent of disease (limited to one lobe or region, unilateral, bilateral, or diffuse) and cavitation status (cavities present [location] or absent) will be documented by validated numerical score for grading chest X-ray in adult smear-positive pulmonary TB (Thorax 2010; 65(10):863-9). Measured through Week 65
Secondary Proportion of participants who have a TB relapse, from end of treatment until Week 65 Measured through Week 65
Secondary Proportion of participants who have a TB recurrence, from end of treatment until Week 65 Measured through Week 65
Secondary Pharmacokinetic parameter for CFZ: Minimum concentration (Cmin) Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13. Measured at Weeks 2 and 13
Secondary Pharmacokinetic parameter for CFZ: Maximum concentration (Cmax) Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13. Measured at Weeks 2 and 13
Secondary Pharmacokinetic parameter for CFZ: Time of Cmax (Tmax) Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13. Measured at Weeks 2 and 13
Secondary Pharmacokinetic parameter for CFZ: Area under the concentration curve (AUC0-24h) Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13. Measured at Weeks 2 and 13
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2